Stablepharma Limited 's proprietary StablevaX platform reformulates temperature-sensitive vaccines and medicines into thermostable, fridge-free products.

Stablepharma Ltd is an innovative biopharmaceutical company developing a pipeline of fridge-free vaccine and pharmaceutical products. Stablepharma was founded with a simple purpose; to use its novel technology to dramatically improve health outcomes for those adults and children most at risk of death and disability caused by vaccine preventable diseases. StablevaX is an adaptable fridge-free technology which offers a greatly extended shelf-life, reduces vaccine wastage and CO2 emissions of the global cold-chain. The WHO estimate that approximately 50% of all vaccines manufactured are wasted due to failures in the global cold chain (distribution and storage of vaccines). Stablepharma aims to ensure that a proportion of vital vaccines and pharmaceutical products can be removed from the refrigerated cold chain and stored for months or even years at room temperature. Stablepharma is developing the worlds first fridge-free vaccine, SPVX02 for Tetanus diphtheria, a pharmaceutical product for the prevention of Tetanus and Diphtheria.